Victory Capital Management’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q3 | – | Sell |
-211,931
| Closed | -$21.6M | – | 2583 |
|
|
2023
Q2 | $21.6M | Buy |
211,931
+50,249
| +31% | +$4.76M | 0.02% | 741 |
|
|
2023
Q1 | $14.7M | Buy |
+161,682
| New | +$9.49M | 0.02% | 892 |
|
|
2022
Q4 | – | Sell |
-11,690
| Closed | -$294K | – | 2747 |
|
|
2022
Q3 | $294K | Buy |
11,690
+651
| +6% | +$18K | ﹤0.01% | 2253 |
|
|
2022
Q2 | $335K | Sell |
11,039
-14
| -0.1% | -$418 | ﹤0.01% | 2205 |
|
|
2022
Q1 | $281K | Sell |
11,053
-73
| -0.7% | -$2.17K | ﹤0.01% | 2321 |
|
|
2021
Q4 | $293K | Sell |
11,126
-1,479
| -12% | -$114K | ﹤0.01% | 2391 |
|
|
2021
Q3 | $1.27M | Sell |
12,605
-132
| -1% | -$15.5K | ﹤0.01% | 1751 |
|
|
2021
Q2 | $1.8M | Sell |
12,737
-577
| -4% | -$65.2K | ﹤0.01% | 1659 |
|
|
2021
Q1 | $1.33M | Sell |
13,314
-658
| -5% | -$76.7K | ﹤0.01% | 1779 |
|
|
2020
Q4 | $1.73M | Sell |
13,972
-1,602
| -10% | -$211K | ﹤0.01% | 1568 |
|
|
2020
Q3 | $1.52M | Sell |
15,574
-5,850
| -27% | -$731K | ﹤0.01% | 1530 |
|
|
2020
Q2 | $3.34M | Sell |
21,424
-20,828
| -49% | -$3.17M | ﹤0.01% | 1269 |
|
|
2020
Q1 | $6.1M | Buy |
42,252
+20,747
| +96% | +$4.01M | 0.01% | 1220 |
|
|
2019
Q4 | $4.4M | Sell |
21,505
-5,837
| -21% | -$1.06M | 0.01% | 1231 |
|
|
2019
Q3 | $2.19M | Buy |
27,342
+26,697
| +4,139% | +$2.27M | ﹤0.01% | 1424 |
|
|
2019
Q2 | $61K | Sell |
645
-322
| -33% | -$27.8K | ﹤0.01% | 1707 |
|
|
2019
Q1 | $83K | Hold |
967
| – | – | ﹤0.01% | 1673 |
|
|
2018
Q4 | $54K | Sell |
967
-184
| -16% | -$11.2K | ﹤0.01% | 1687 |
|
|
2018
Q3 | $94K | Buy |
1,151
+151
| +15% | +$10.6K | ﹤0.01% | 1675 |
|
|
2018
Q2 | $35K | Hold |
1,000
| – | – | ﹤0.01% | 1776 |
|
|
2018
Q1 | $21K | Sell |
1,000
-23,670
| -96% | -$609K | ﹤0.01% | 1789 |
|
|
2017
Q4 | $698K | Buy |
24,670
+2,690
| +12% | +$75.1K | ﹤0.01% | 1287 |
|
|
2017
Q3 | $683K | Buy |
21,980
+950
| +5% | +$28.6K | ﹤0.01% | 1290 |
|
|
2017
Q2 | $665K | Sell |
21,030
-290
| -1% | -$7.13K | ﹤0.01% | 1257 |
|
|
2017
Q1 | $483K | Buy |
+21,320
| New | +$527K | ﹤0.01% | 1314 |
|
Other funds holding RETA
Victory Capital Management's RETA Position: Q3 2023 in Review
Victory Capital Management sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q3 2023, closing a stake of 211,931 shares — an estimated $21.6M sold.
Victory Capital Management first reported a position in RETA in Q1 2017 and held it in 25 quarters. The position peaked at $21.6M in Q2 2023. 2 funds tracked by Wall St. Rank hold RETA as of Q3 2023.
- Victory Capital Management reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q3 2023 after selling out during the quarter.
- Victory Capital Management sold 211,931 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q3 2023, an estimated $21.6M.
- Victory Capital Management first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q1 2017 and held it in 25 quarters.
- Victory Capital Management's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $21.6M in Q2 2023.
- 2 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q3 2023.
Based on Victory Capital Management's 13F filing for Q3 2023, filed 6 Nov 2023.